Literature DB >> 12107202

Hydrochlorothiazide effectively reduces urinary calcium excretion in two Japanese patients with gain-of-function mutations of the calcium-sensing receptor gene.

Kohei Sato1, Yukihiro Hasegawa, Jun Nakae, Kenji Nanao, Ikuko Takahashi, Toshihiro Tajima, Nozomi Shinohara, Kenji Fujieda.   

Abstract

Gain-of-function mutations of the calcium-sensing receptor (CaR) gene cause autosomal dominant and/or sporadic hypocalcemia with hypercalciuria. Because treatment of the hypocalcemia with vitamin D and/or calcium in patients with such mutations results in increased hypercalciuria, nephrocalcinosis, and renal impairment, its use should be limited to alleviating the symptoms of symptomatic patients. Because thiazide diuretics have been successfully used to treat patients with hypercalciuria and hypoparathyroidism, they are theoretically useful in reducing urine calcium excretion and maintaining serum calcium levels in patients with gain-of-function mutations of the CaR gene. In this study, we report on the clinical course, molecular analysis, and effects of hydrochlorothiazide therapy in two Japanese patients with gain-of-function mutations of the CaR gene. Within a few weeks after birth, they developed generalized tonic seizures due to hypocalcemia (serum calcium values: 1.1 mmol/liter and 1.3 mmol/liter, respectively). Despite treatment with the standard dose of 1,25-dihydroxyvitamin D(3) in one patient and 1alpha-hydroxyvitamin D(3) in the other, acceptable serum calcium levels near the lower limit of normal were not established, and their urinary calcium excretion inappropriately increased. Addition of hydrochlorothiazide (1 mg/kg) reduced their urinary calcium excretion and maintained their serum calcium concentrations near the lower limit of normal, allowing the 1,25-dihydroxyvitamin D(3) and 1alpha-hydroxyvitamin D(3) doses to be reduced, and it alleviated their symptoms. A heterozygous missense mutation was identified in both patients. In one patient, the mutation was A843E in the seventh transmembrane domain of the CaR, and in the other it was L125P in the N-terminal extracellular domain. In vitro transient transfection of their mutant CaR cDNAs into HEK293 cells shifted the concentration-response curve of Ca(2+) to the left. In conclusion, two sporadic cases of hypercalciuric hypocalcemia were due to de novo gain-of-function mutations of the CaR gene. Hydrochlorothiazide with vitamin D(3) successfully reduced the patients' urinary calcium excretion and controlled their serum calcium concentrations and symptoms. Thiazide diuretics are effective in patients with gain-of function mutations of the CaR gene.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107202     DOI: 10.1210/jcem.87.7.8639

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  A physiologic-based approach to the evaluation of a patient with hyperphosphatemia.

Authors:  David E Leaf; Myles Wolf
Journal:  Am J Kidney Dis       Date:  2012-08-30       Impact factor: 8.860

Review 2.  Calcium sensing by endocrine cells.

Authors:  Edward M Brown
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

3.  Genetic analysis and identification of novel variations in Chinese patients with pediatric epilepsy by whole-exome sequencing.

Authors:  Xuechao Zhao; Haofeng Ning; Yanhong Wang; Ganye Zhao; Shiyue Mei; Ning Liu; Conghui Wang; Aojie Cai; Erhu Wei; Xiangdong Kong
Journal:  Neurol Sci       Date:  2022-02-26       Impact factor: 3.307

4.  Action of thiazide on renal interstitial calcium.

Authors:  Shaleka L Eley; Crystal M Allen; Cicely L Williams; Richard D Bukoski; Mildred A Pointer
Journal:  Am J Hypertens       Date:  2008-05-01       Impact factor: 2.689

5.  Calcium-sensing receptor sequencing in 21 patients with idiopathic or familial parathyroid disorder: pitfalls and characterization of a novel I32 V loss-of-function mutation.

Authors:  Auryan Szalat; Michal Shahar; Shoshana Shpitzen; Boaz Nachmias; Gabriel Munter; David Gillis; Ronen Durst; Dror Mevorach; Eran Leitersdorf; Vardiella Meiner; Haim Rosen
Journal:  Endocrine       Date:  2014-08-05       Impact factor: 3.633

6.  Pathogenesis of hypokalemia in autosomal dominant hypocalcemia type 1.

Authors:  Naohiro Kamiyoshi; Kandai Nozu; Yoshimichi Urahama; Natsuki Matsunoshita; Tomohiko Yamamura; Shogo Minamikawa; Takeshi Ninchoji; Naoya Morisada; Koichi Nakanishi; Hiroshi Kaito; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-09-01       Impact factor: 2.801

7.  A novel gain-of-function mutation (F821L) in the transmembrane domain of calcium-sensing receptor is a cause of severe sporadic hypoparathyroidism.

Authors:  Masaaki Shiohara; Tetsuo Mori; Bai Mei; Edward M Brown; Tomoyuki Watanabe; Toshiyuki Yasuda
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

8.  Novel Mutation in the CASR Gene (p.Leu123Ser) in a Case of Autosomal Dominant Hypocalcemia.

Authors:  Joana Regala; Branca Cavaco; Rita Domingues; Catarina Limbert; Lurdes Lopes
Journal:  J Pediatr Genet       Date:  2015-03

Review 9.  PTH replacement therapy of hypoparathyroidism.

Authors:  L Rejnmark; T Sikjaer; L Underbjerg; L Mosekilde
Journal:  Osteoporos Int       Date:  2012-11-27       Impact factor: 4.507

Review 10.  The Molecular Basis of Calcium and Phosphorus Inherited Metabolic Disorders.

Authors:  Anna Papadopoulou; Evangelia Bountouvi; Fotini-Eleni Karachaliou
Journal:  Genes (Basel)       Date:  2021-05-13       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.